Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI
US11052162B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2017 |
| Grant date | Jul 6, 2021 |
| Priority date | — |
| Expiry date | Mar 13, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F5/003
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.